In the September issue of Pharmaceutical Executive, Lev Gerlovin addresses four main questions that US drugmakers must answer to cope with the evolving payer landscape given rising drug prices. To read the article, click the link below.
Inflation Reduction Act: Reforms to patient cost-sharing
The Inflation Reduction Act (IRA) of 2022 contains some of the most significant changes in healthcare regulation since the introduction of the Medicare...